SCHEMBL2937340

SCHEMBL2937340

O=C(Nc1cc(CN2CC(=O)N(c3ccc(OC(F)(F)F)cc3)C2=O)ccn1)c1ccco1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.40
PPARA Q07869 2/20 0.40
LCLAT1 Q6UWP7 1/20 0.40
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
SMN1; SMN2 Q16637 6/20 0.39
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
CYP1A2 P05177 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
IGF1R P08069 2/20 0.38
ABL1 P00519 1/20 0.38
KCNH2 Q12809 1/20 0.38
HSD17B10 Q99714 2/20 0.37
TP53 P04637 3/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SRPK1 Q96SB4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2941540 0.88 PPARD (0.45) PPARDPPARANPC1RAB9AMAPK10
SCHEMBL2942029 0.87 IGF1R (0.52) SMN1; SMN2NPC1RAB9ACYP1A2MAPK8
SCHEMBL2935705 0.86 IGF1R (0.50) PPARDPPARAIGF1RPPARG
SCHEMBL2943366 0.86 NR3C2 (0.45) PPARDPPARAIGF1RPPARG
SCHEMBL6173434 0.86 NPC1 (0.41) LCLAT1SMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL2940329 0.86 RAB9A (0.39) PPARDPPARASMN1; SMN2NPC1RAB9A
SCHEMBL2937368 0.86 GCGR (0.43) PPARDPPARANPC1RAB9APPARG
SCHEMBL2938088 0.86 ACKR3 (0.44) PPARDPPARAKCNQ3KCNQ2SMN1; SMN2
SCHEMBL3728230 0.86 CACNA1H (0.49) PPARDPPARAIGF1RPPARG
SCHEMBL2933988 0.85 TDP1 (0.44) PPARDPPARASMN1; SMN2KMT2AIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 PPARD 3189/4885PPARA 4338/4885LCLAT1 3911/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA PPARD 3572/4885PPARA 4692/4885LCLAT1 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.